EDIT - Editas Medicine Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)
2024-02-13 13:14:10 ET
Editas Medicine, Inc. (EDIT)
Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 13, 2024 08:40 AM ET
Company Participants
Dr. Baisong Mei - Senior Vice President and Chief Medical Officer
Conference Call Participants
Jay Olson - Oppenheimer
Presentation
Jay Olson
Hello everyone and welcome to Oppenheimer’s 34th Annual Healthcare Conference. I am Jay Olson, one of the biotech analysts at Oppenheimer and I want to thank you for joining us. It's my pleasure to welcome Editas to our conference, and it's an honor to introduce Dr. Baisong Mei, Senior Vice President and Chief Medical Officer. [Operator Instructions]
And with that, we'll get started. Thank you so much for joining us, Baisong.
Dr. Baisong Mei
Thank you for the opportunity, Jay.
Question-and-Answer Session
Q - Jay Olson
Our pleasure. So maybe just to get started, congrats on all the progress you've made in the past year. Can you just give us a brief summary of Editas for those who may not be familiar with your story, and also, if you could highlight some of the recent updates? That would be great.
Dr. Baisong Mei
Thank you. Happy to Jay. Editas is a clinical stage company. We specialize in a CRISPR-mediated genome editing. We are pioneer in the gene editing space, and we just celebrated our 10th anniversary last year. We have a strong scientific foundation in gene editing space. Since our CEO, Gilmore O'Neill, joined about 18 months ago, Editas is going through a transformation from a technology platform company to become a commercial therapeutic company. So that's our goal....
Editas Medicine, Inc. (EDIT) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)